Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Rare Tumour × camrelizumab × Clear all

Phase

Status

Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 36 Carcinoma, Non-Small-Cell Lung 19 Stomach Neoplasms 17 Triple Negative Breast Neoplasms 16 Nasopharyngeal Carcinoma 16 Esophageal Squamous Cell Carcinoma 14 Esophageal Neoplasms 14 Squamous Cell Carcinoma of Head and Neck 13 Breast Neoplasms 12 Colorectal Neoplasms 10 Uterine Cervical Neoplasms 8 Pancreatic Neoplasms 7 Recurrence 6 Neoplasm Metastasis 6 Melanoma 6 Liver Neoplasms 6 Lung Neoplasms 5 Cholangiocarcinoma 5 Biliary Tract Neoplasms 5 Neoplasms 4 Locally Advanced Gastric Cancer 4 Hodgkin Disease 4 Advanced Gastric Cancer 4 Sarcoma 3 Rectal Neoplasms 3 Osteosarcoma 3 Nasopharyngeal Neoplasms 3 Glioblastoma 3 Gestational Trophoblastic Disease 3 Urinary Bladder Neoplasms 2

Interventions

toripalimab 1 tislelizumab 1 sintilimab 1 pyrotinib 1 pembrolizumab 1 pamiparib 1 palbociclib 1 osimertinib 1 neratinib 1 erdafitinib 1 envafolimab 1 entrectinib 1 durvalumab 1 camrelizumab 1 atezolizumab 1 alectinib 1 Vinorelbine 1 Vemurafenib 1 Teniposide 1 Nivolumab 1 Irinotecan 1 Imatinib Mesylate 1 Gemcitabine 1 Fluorouracil 1 Epirubicin 1 Cisplatin 1 Albumin-Bound Paclitaxel 1 1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06692491 2024-11-18

SPRING

Peking University Shenzhen Hospital

Phase 2 Not yet recruiting

Rare Tumour

Data powered by HemOnc (CC BY 4.0) Colophon ⚡